Alkermes (ALKS)
(Delayed Data from NSDQ)
$24.68 USD
+0.24 (0.98%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $24.69 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
ALKS 24.68 +0.24(0.98%)
Will ALKS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALKS
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Other News for ALKS
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Alkermes initiates Phase 2 clinical trial of ALKS 2680
First Week of June 21st Options Trading For Alkermes (ALKS)
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)